Rationale: MicroRNAs (miRs) are expanding our understanding of cardiac disease and have the potential to transform cardiovascular therapeutics. One miR can target hundreds of individual mRNAs, but existing methodologies are not sufficient to accurately and comprehensively identify these mRNA targets in vivo.
M icroRNAs (miRs) are small, noncoding RNAs that regulate critical aspects of cell function including growth, differentiation, and programmed death. These Ϸ22nucleotide single-stranded oligomers bind through Watson-Crick base-pairing to complementary sequences in mRNA targets, thereby accelerating mRNA degradation or interfering with protein translation. miRs play essential roles is tissue development and homeostasis, and their capacity to act as mediators of disease have been demonstrated in multiple conditions and organ systems. [1] [2] [3] The effects of miRs accrue from their binding to specific mRNA targets. Bioinformatics analysis has suggested that 30% of all mRNAs may be regulated by miRs. Because a single miR can bind to dozens or hundreds of different mRNAs, it has the potential to orchestrate complex gene networks and equally complicated phenotypes. For this reason, there is tremendous interest in developing miR antagonists and/or mimetics for clinical therapeutics. 4 Before the therapeutic potential of miRs can be fulfilled, however, the full spectrum of their specific mRNA targets needs to be determined in the context of the organ system and pathophys-iological processes of interest. Achieving this goal has lagged behind experimental miR manipulation and characterization of resulting phenotypes. 5 One approach for identifying miR targets compares miR and mRNA expression signatures to detect reciprocally regulated miR-mRNA pairs. 6 This approach is limited because only a fraction of miR effects are mediated through mRNA destabilization (the remainder by translational suppression 7 ) and because indirect miR effects can regulate mRNAs that are not direct targets. 8 Bioinformatics have also been used to identify putative mRNA targets based on miR antisense sequence pairing to mRNA 3Ј untranslated regions (UTRs), evolutionary conservation, and the predicted binding energy of miR-mRNA duplexes. However, different bioinformatics platforms differ markedly in their predictions, 9 and even if the predictions are accurate, bioinformatics does not provide information about biological context. Thus, techniques are needed for comprehensive, unbiased in vivo identification of miR targets in health and disease.
An approach of isolating mRNAs sequestered by miRs into RNA-induced silencing complexes (RISCs) has been used to profile miR-targeted mRNAs in cultured cells and mouse brains. 10, 11 Although conceptually attractive, this technique has been limited in practice by use of microarrays requiring RNA amplification, which is a potential source of experimental error. Here, we reveal the extent to which RNA amplification biases transcriptional profiling. To avoid this confounder, we describe a technique for annotation and quantitation of mRNAs in the RNA-induced sequencing complexes (the "RISCome") of mouse hearts using next generation massively parallel sequencing of unamplified mRNAs isolated from myocardial Argonaute (Ago)2 immune complexes. By "programming" the cardiomyocytes with excess miR, we then applied the technique to identification of cardiomyocyteautonomous mRNA targets for 2 structurally and functionally distinct cardiac-expressed miRs, miR-133a, and miR-499. These procedures are applicable to any miR in any tissue and disease state and will complement mRNA footprinting 11 and proteomics analyses 12 to predict in vivo effects of proposed miR-based therapeutics.
Methods

Preparation and Quantification of Total Myocardial RNA
Cardiac miR-133a transgenic mice have been described previously. 13 miR-499 transgenic mice were generated similarly by cloning a 530-bp fragment surrounding the mature mouse miR-499 sequence (chromosome 2, intron 19 of Myh7b) into the Myh6 promoter construct. Total cardiac RNA was isolated from flash-frozen ventricular tissue using TRIzol (Invitrogen) and quantified on a UV spectrometer.
Reverse Transcription and Preparation of cDNA
Preparation of cDNA fragments was modified from previously described protocols. 8, 14 For poly(A) ϩ RNA, 4 g of total cardiac RNA isolated from ventricular apices was twice oligo(dT)-selected using the Dynabead mRNA purification system (Invitrogen). A total of 200 ng of cardiac mRNA was fragmented to Ϸ200 nucleotides by heating to 94°C for 2.5 minutes in 40 mmol/L Tris acetate pH 8.2, 100 mmol/L potassium acetate, 30 mmol/L magnesium acetate, and immediately chilled on ice. After purification on Ambion NucAway columns, 100 ng of fragmented cardiac mRNA was reversetranscribed using SuperScript III (Invitrogen) with random hexamers according to the directions of the manufacturer (50 minutes, 50°C), followed by second-strand cDNA synthesis for 2 hours, 16°C, in 20 mmol/L Tris-HCl pH 6.9, 90 mmol/L KCl, 4.6 mmol/L MgCl 2 , 150 mmol/L ␤-NAD ϩ , 10 mmol/L (NH 4 ) 2 SO 4 , 0.067 U/L Escherichia coli DNA ligase, 0.27 U/L E coli DNA polymerase I, and 0.013 U/L E coli RNase H (New England Biolabs).
Integrated Reverse Transcription and Amplification of Low-Input RNA
RNA amplification before fragmentation and sequencing library construction was performed according to Mitreva and Mardis. 15 Briefly, polyA-tailed RNA was selected from total RNA using a primer recognizing 5Ј mRNA ends and a primer containing an oligo(dT) moiety. Following reverse transcription, a third primer recognizing common elements in the first 2 primers was used to amplify cDNAs and to add biotin tags (primer sequences as described in 15 ). Optimization of amplification cycles was performed as described, 15 and biotin tags were removed on streptavidin beads following restriction enzyme digestion.
Immunoprecipitation of Mouse Cardiac Ago2-Associated RNA and Preparation of cDNA
Conditions for Ago2 immunoprecipitation were adapted from Karginov et al. 10 Frozen mouse heart bases were homogenized in 500 L of ice-cold 50 mmol/L Tris-HCl, 5 mmol/L EDTA, 5 mmol/L EGTA, pH 7.5, with Roche Complete protease inhibitors. Yeast tRNA (Invitrogen) and SUPERnase-IN (Ambion) were added to final concentrations of 1 mg/mL and 1 U/L, respectively, and unbroken cellular material was removed at 100g, 5 minutes, 4°C . Nonidet P-40 was added to a final concentration of 0.5% (wt/vol) to solubilize proteins (15 minutes, 4°C, rotating) and insoluble material was removed at 10 000g, 15 minutes, 4°C. The supernatant was added to 50 L of protein G-coupled Dynabeads (Invitrogen), to which 5 g of antimouse Ago2 monoclonal antibody (Wako Pure, clone no. 2D4, lot PEM0820) had been previously bound according to the Dynabead protocol. Following 1 hour of rotational incubation at 4°C, the beads were washed 3 times with Dynabead washing buffer, transferring the suspension to a fresh tube for the last wash. Beads were pelleted from the remaining suspension, the supernatant was removed, and 500 L of TRIzol was added to the immunoprecipitated material to extract RNA. Ago2 immunoprecipitate-associated RNA was fragmented in acetate buffer without poly-A ϩ selection, purified on NucAway columns, and one-half was used for cDNA synthesis using the protocol described above.
Construction of DNA-Barcoded Short-Read Libraries for Illumina Sequencing
Detailed methods for preparation of Illumina sequencing libraries from mouse cardiac RNA have been described recently. 8 Briefly, cDNAs were end-repaired and 3Ј A-overhangs added. Illumina adapters with T-overhangs and customized to include 3-nucleotide "barcodes" were ligated to the cDNA at 10:1 molar excess and DNA in the 200-to 400-bp range was isolated via gel purification (Qiagen) on 2% low-melting agarose. One-third of the gel-purified material was amplified with 12 cycles (total myocardial cDNA) or 16 cycles (RISC-immunoprecipitated cDNA) of Phusion polymerase-mediated (New England Biolabs, no. F531) PCR (10 seconds, 98°C; 30 seconds, 65°C; 30 seconds, 72°C; followed by final 5 minutes at 72°C), using oligonucleotides complementary to Illumina sequencing adapters. The final, amplified libraries were again columnpurified and quantified using PicoGreen (Quant-It, Invitrogen).
Four barcoded libraries were combined in equimolar (10 nmol/L) amounts and diluted to 6 pmol/L for cluster formation on a single Illumina Genome Analyzer II flow cell lane, followed by single-end sequencing. Base calling, library sorting by barcode, and mapping to the transcriptome were performed as described previously, 8 using updated versions of the software packages Bowtie (release 0.12.3), 16 TopHat (release 1.0.13), 17 and Cufflinks (release 0.8.1). 18 Cufflinks outputs gene expression values in terms of FPKM (fragments per kilobase of exon per million mapped reads). 18 When performing single-end Illumina sequencing, as we have done here, this parameter is equivalent to RPKM (reads per kilobase of exon per million mapped reads), in which an RPKM of 3 corresponds to 1 copy per cell in cardiac samples. 8, 14 We used the default options supplied with these software packages in our analyses and analyzed only those RNA elements that had expression signals in at least 2 of 4 biological replicates. 
Non-standard Abbreviations and Acronyms
Computation of RISC Abundance and Enrichment Scores
Because they are not poly-A ϩ -selected, RISCome sequencing libraries contained a higher proportion of ribosomal RNA (32% to 42%) than poly-A ϩ -selected transcriptome libraries (3% to 5%). To permit comparison between the transcriptome and RISCome, measures of RNA abundance expressed as FPKM 18 were adjusted for the proportion of mRNA. RISC enrichment scores to assess RISC enrichment or depletion were defined as (RISComeadjusted FPKM/transcriptome-adjusted FPKM) of Ն2.0 or Յ0.5; PϽ0.0001; false discovery rate Ͻ0.01. Scores of Ͻ1 were plotted as Ϫ1 per score for clarity.
Luciferase Reporter Constructs
Full (if Յ1 kb) or partial (regions selected to contain miR-133a binding "seeds") 3Ј UTRs of candidate miR-133a target genes were cloned into the dual-luciferase reporter vector psiCheck2 (Promega). The miR-133a genomic precursor was the same as that used to create miR-133a transgenic mice. 13 A total of 100 ng of psiCheck2 construct, together with 100 ng of pcDNA3.1 or pcDNA3.1ϩmiR-133a genomic precursor, was transfected in triplicate into HEK293 cells on 24-well plates using Fugene HD (Promega). After 48 hours, duplicate determinations of Renilla and firefly luciferase activities were performed after harvesting cells into 120 L of Glo Lysis Buffer (Promega). Each lysate (30 L) was analyzed using Dual-Glo Luciferase reagents (Promega) on a SpectraMax M5e plate reader (Molecular Devices). Renilla 3Ј UTR-coupled luciferase activity was normalized to constitutive firefly luciferase activity for each well.
Statistical Analysis
Gene symbols and FPKM values were imported into Partek Genomics Suite (version 6.5; Partek, St Louis, Mo) for comparison of RISCome and transcriptome expression values, computation of probability values and false discovery rates, and preparation of probability value versus fold change (volcano) plots. GraphPad Prism was used for 2 tests. Luciferase activities were compared using Student t test (GraphPad Prism). Gene ontology overrepresentation was performed using a hypergeometric test with Benjamini-Hochberg false discovery rate correction. 19 Significant differences were defined as PϽ0.05 unless otherwise described.
Results
RNA Amplification Biases mRNA Expression Signatures
miR-mRNA pairings in any tissue depend on at least 3 factors: the identity and quantity of expressed miRs, the identity and quantity of expressed mRNAs, and the potential for those miRs and mRNAs to interact via sequence complementarity. The former 2 factors vary with tissue type and pathological circumstance. It is therefore necessary to profile miR-mRNA interactions in the proper biological context. Previous RNA profiling of RISC-associated mRNA used expression microarrays, which require RNA amplification that might alter the apparent transcriptional signature. 10, 11 To determine the effect of mRNA amplification on transcript profiling, we compared mRNA signatures of amplified and nonamplified mRNA from the same mouse heart samples. A total of 5 g of unamplified total mouse cardiac RNA underwent 2 poly-A ϩ selections to yield 150 ng of mRNA for reverse transcription, sequencing library production, and RNA sequencing on an Illumina Genome Analyzer II. 8 In parallel, 50 ng of the same total mouse cardiac RNA (ie, 1/100th the above initial input amount) was poly-A ϩ -selected, reverse-transcribed, and amplified using an integrated multistage procedure developed specifically for expression profiling of limited RNA samples, 15 and Illumina sequencing libraries were prepared (Figure 1 , left pathway). Sequencing depth was similar in the 2 samples (9.5ϫ10 5 mRNAmatching reads in the reference sample versus 8.5ϫ10 5 in the amplified sample), but whereas 10 501 individual mRNAs were identified from unamplified cardiac RNA, only 5610 transcripts were detected after RNA amplification. Only 53% of cardiac-expressed mRNAs were represented in sequencing libraries prepared from amplified mRNA (Figure 1 , left graph, red data points), and correlation of RNA expression levels between amplified and nonamplified RNAs from the same heart was poor (r 2 ϭ0.25; Figure 1 , left), even compared with RNA sequencing from 2 separate normal hearts 8 (r 2 ϭ0.92; Figure I in the Online Data Supplement, available at http://circres.ahajournals.org). Similar amplification bias was evident when comparing normal and cardiomyopathic hearts (Online Figure II) . These results show that RNA amplification is a source of error in mRNA profiling.
We considered that small amounts of mRNA might be accurately profiled if the mRNA was fragmented and cDNA sequencing libraries were constructed before any amplification ( Figure 1 , right pathway). To test this, RNA-sequencing libraries were prepared from 100 or 0.5 ng poly-A ϩ -twiceselected mRNA from the same normal mouse heart. In contrast to amplified mRNA (in which 47% of mRNA transcripts were not represented and the correlation of expression values for represented RNAs was poor), sequencing library preparation from unamplified low-input RNA detected 99.2% of mRNA transcripts in the highinput library prepared from the same sample (9336 of 9564 transcripts) with excellent correlation of RNA expression levels (r 2 ϭ0.93; Figure 1, right) . Thus, next-generation sequencing library production from unamplified RNA generates accurate expression profiles from very small amounts of mRNA.
Defining the Cardiac RISCome Profiling by Deep RNA Sequencing of Ago2 Complexes
Quantitative analysis of mRNAs sequestered in murine cardiac RISC complexes (the cardiac RISCome) could define the subset of cardiac-expressed transcripts targeted by cardiacexpressed miRs. Performing this analysis in vivo is essential to determining how the RISCome is modified in health and disease. As a first step toward using RNA sequencing to define mRNAs recruited into individual mouse cardiac RISComes (a technique that we call RISC-Seq), we developed procedures for isolating the RISC complexes from mouse hearts, capturing the associated mRNAs, and processing the RISC-mRNA libraries for sequencing.
The RISC consists of Ago1 and -2 proteins, TNRC6 family members, miRs, and their mRNA targets. 20 After identifying an antibody that immunoprecipitates endogenous Ago2 from mouse hearts (Figure 2a ), we determined whether endogenous cardiac Ago2 immunoprecipitates contained sufficient RISC-associated cardiac mRNA for RNA sequence analysis without sample crosslinking, amplification, or pooling previously used with Ago2 pull-down. 10, 11 Ventricular tissue from four 8-week-old male FVB/N mouse hearts was transversely sectioned; one-third of each heart was used for mRNA sequencing to characterize the overall cardiac transcriptomes, and the remaining two-thirds were used for Ago2 immunoprecipitation, RNA extraction, and RISCome RNA-sequencing analysis. Although there was 96.5% overlap in the individual mRNAs represented in the cardiac transcriptome and RISCome (9779Ϯ894 transcriptome mRNAs and 10 690Ϯ205 RISCome mRNAs; Pϭ0.31), 1645 individual mRNAs (Ϸ15% of the cardiac transcriptome) were significantly RISC-enriched in the Ago2 immunoprecipitates (Figure 2b) . RISC enrichment or depletion was defined as (RISCome expression/transcriptome expression) of Ն2.0 or Յ0.5; PϽ0.0001; false discovery rate Ͻ0.01. The enriched Table I ).
Published studies have identified 139 consensus cardiacexpressed miRs (Online Table II ). 4, 21 Because the mouse cardiac RISCome should consist of mRNAs that interact with these (and any other) cardiac-expressed miRs, we compared our results with RISC-Seq to the targets predicted for these 139 cardiac-expressed miRs by the TargetScan algorithm. 12, 22 A total of 1171 of 1645 RISC-enriched mRNAs (71.2%) were predicted targets of one or more cardiac-expressed miRs (Figure 2d ), compared with only 45.7% of all cardiacexpressed mRNAs. By contrast, only 8 of 75 RISC-depleted mRNAs (10.7%) are predicted cardiac miR targets ( Figure  2d ; Pϭ0.0003, Fisher exact test). Thus, our RISC-Seq results are supported by bioinformatic predictions based on established cardiac miR expression signatures.
RISC enrichment scoring ranks transcripts by abundance in RISCome relative to transcriptome (simply: [RISC-mRNA]/ [transcript mRNA] for each individual mRNA). Thus, reciprocal regulation of mRNAs in the RISCome and transcriptome, as expected with miR-induced mRNA destabilization, produces a higher score. Because this ranking method does not account for absolute mRNA expression, a transcript expressed at 1 copy per cell and enriched 2-fold in the RISC is scored the same as a transcript having 50 copies per cell with similar RISC enrichment. To determine whether the absolute number of mRNA copies in the RISCome provided critical information about miR targets, we ranked the RISCassociated transcripts according to their absolute abundance and determined the proportion of TargetScan-predicted cardiac miR targets by quintile. RISC-associated mRNA abundance and the likelihood of being a predicted cardiac miR target were associated (PϽ0.01, 2 test; Figure 3a) , demonstrating that absolute RISC mRNA abundance is a factor in miR targeting. Surprisingly, however, the association between RISC enrichment score and either transcriptome mRNA abundance (Figure 3b ) or RISC-associated mRNA abundance (Figure 3c) is inverted, revealing that the most RISC-enriched targets tend to be the rarer mRNA transcripts. This finding is consistent with previous observations that most abundant cardiac mRNAs, encoding myofilament and other constitutively expressed proteins, tend to undergo the least regulation. 8, 23 These results indicate that the analytic approach of relating RISC mRNA abundance to transcript mRNA abundance, ie, RISC enrichment, is superior to just identifying mRNAs in the RISCome.
Programming of the Cardiac RISCome to Identify Individual miR Targets
A thorough understanding of the pathological roles of dysregulated miRs requires delineating individual in vivo miR-mRNA functional pairs, which has been problematic using bioinformatics predictions and tissue culture experimentation. 13 We considered that the cardiomyocyte RISC could be programmed to retain specific miR-targeted mRNAs 10 by cardiomyocyte-specific overexpression of a miR precursor. RISC-Seq comparison of miR-programmed and unpro- grammed cardiac RISComes would then identify mRNAs targeted by the programming miR. We tested this notion using RISC-Seq of our miR-133a transgenic mice. 13 miR-133a is a muscle-specific miR essential for cardiac development that is dysregulated in cardiac disease. 24 -27 Importantly, miR-133a transgenic mice have no basal cardiac phenotype to confound miR target analysis by dysregulating cardiac gene expression.
RNA sequencing of the miR-133a-programmed transcriptome and RISCome was performed as described above. Sequencing read depth (1.5 to 2.0ϫ10 6 mRNA-matching reads per barcoded sample), alignment to the mouse genome, and the identities of detected transcripts were similar for all 16 libraries (1 RNA-seq and 1 RISC-seq library from each of 4 nontransgenic and 4 miR-133a transgenic mice). RISC scoring identified 2149 RISC-enriched mRNAs in miR-133aprogrammed hearts, 684 of which had not met criteria for being RISC-enriched in nontransgenic hearts ("new miR-133a targets"), and 209 of which were enriched to a significantly greater extent (Ͼ1.3-fold greater RISC score, PϽ0.001, 2 test) in the miR-133a cardiac RISCome ("hyperenriched miR-133a targets") ( Figure 4a and Online Table III ). TargetScan reports only 435 predicted mouse miR-133a targets among 17 315 total mouse transcripts in the database: 310 of these mRNAs are among the Ϸ10 000 mRNAs present in the cardiac transcriptome (Ϸ2.8% of all cardiac-expressed mRNAs). The 1645 mRNAs enriched in the normal cardiac RISCome contain 107 (34.5%) of the 310 TargetScan predicted cardiac miR-133a targets, consistent with miR-133a being one of the more highly expressed cardiac miRs. 6, 25 Finally, 147 (47.4%) of the 310 predicted targets were present in miR-133aprogrammed transcriptomes (Figure 4b) . Thus, bioinformatics analysis shows a progressive increase in the proportion of predicted miR-133a targets from the cardiac transcriptome to the cardiac RISCome and to the miR-133a-programmed cardiac RISCome.
Enrichment of miR-133a targets in programmed cardiac RISCs and the presence of miR-133a-programmed RISC mRNAs previously shown to be miR-133a targets (Whsc2, 25 Hcn4, 28 Ccnd2, 27 Casp9, 29 and Ctgf 28 ; only Whsc2 and Ctgf predicted by TargetScan) validated our method of individual miR target analysis by programmed RISC-Seq. However, a number of miR-133a-programmed RISC-enriched mRNAs identified experimentally were not predicted by TargetScan.
To determine the reason for this discrepancy, we characterized miR-133a effects on 7 miR-133a-programmed RISCassociated mRNAs using standard luciferase reporter assays. 3,10 All 5 miR-133a RISC-enriched mRNA 3Ј UTRs were significantly suppressed by miR-133a ( Figure 5 ), including 3 (Fosl2, Ppargc1b, and Sdc3) that were not identified by TargetScan as miR-133a targets. Only 1 of the 2 TargetScan-predicted/RISC-Seq not predicted miR-133a targets was suppressed (Edem1, which was indeed increased 2.5-fold in miR-133a-programmed RISComes, but with a probability value [0.016] that did not meet our selection criteria) ( Figure 5 ). Based on these results and the 5 previously validated miR-133a targets, RISC-Seq exhibits a sensitivity of 91% for target identification, versus 45% for TargetScan.
RISC-Seq Comparison of miR-133a and miR-499 Programmed Cardiac RISComes
The true applicability of any research technique is its ability to answer a real-world question. Accordingly, we used RISC-Seq to compare in vivo mRNA targeting of 2 cardiacexpressed, but functionally divergent, miRs. miR-133a and miR-499 are both muscle-specific miRs that are expressed at high levels in the heart and are regulated in cardiac disease. 30 Importantly, they belong to different miR subfamilies ( Figure  6 top). The distinct functions and lack of sequence homology of these 2 miRs suggest that they target different mRNAs. Indeed, the population of hyperenriched mRNAs in miR-133a-programmed RISComes has little in common with that from miR-499 transgenic mouse hearts ( Figure 6 bottom; Online Table IV) ; gene ontology classification 19 of the miR-133a and miR-499 programmed RISComes showed significant overrepresentation (see Methods) of cardiac development genes for miR-133a and myofibrillar transcriptional control (biopolymer biosynthesis) genes for miR-499. Thus, the results of RISC-Seq are consistent with the previously established biological effects of these 2 functionally divergent cardiac-expressed miRs. 27, 31 
Discussion
Here, we describe RISC-Seq, a method that marries RNA sequencing to Ago2 immunoprecipitation for in vivo RISCome profiling and identification of specific miR targets. Our method avoids experimental bias introduced by RNA amplification and takes advantage of superior mRNA-profiling results from RNA sequencing, compared with expression arrays. 8 Because our technique works with endogenous Ago2 protein and does not require crosslinking or sample pooling, it is broadly applicable to miR target analysis in genetically and physiologically modeled in vivo models. The cardiac system is especially well suited for analysis of endogenous miR targets because miR effects are central to embryonic heart formation, reactive cardiac hypertrophy, excitation-contraction coupling, and programmed cardiomyocyte death. 4 miR expression is dynamically regulated in heart disease, 6 and so miRs are being evaluated as diagnostic tools and therapeutic targets. 6, 32, 33 The complement of individual cardiac-expressed mRNAs that are potentially regulated by cardiac-expressed miRs (ie, the cardiac RISCome) was not previously known. Here, RISC-Seq defined the normal cardiac RISCome consisting of Ϸ2000 of Ϸ10 000 cardiac-expressed mRNAs. Thus, Ϸ20% of cardiac mRNAs are regulated by miRs under normal conditions. RISC-Seq should be equally useful to define RISC-associated mRNAs in pathological conditions, such as cardiac hypertrophy or heart failure, where the miRome and transcriptome are jointly dysregulated.
Our studies show that absolute RISC-associated mRNA abundance is inferior to RISC enrichment in identifying miR targets. Loosely associated, highly abundant transcriptome mRNAs are unavoidably captured during Ago2 immunoprecipitation, explaining the nearly complete representation of cardiac-expressed mRNAs in the RISC complexes. We controlled for nonspecific representation of highly expressed transcripts in Ago2 immunoprecipitates by relating their abundance in the RISCome to that in the transcriptome, setting a threshold level of 2-fold enrichment. We found that lower abundance mRNAs were disproportionately recruited to the RISCome, consistent with recent results demonstrating that the most abundant mRNA transcripts are also subjected to less transcriptional regulation in disease. 8, 23 To attack the question of individual miR targeting in the heart, we used cardiomyocyte-specific transgenic expression of miR-133a and miR-499 precursors to "program" the cardiomyocyte RISCome. 10 These 2 well-studied miRs have central roles in cardiac development and myofilament identity, respectively, 30 and are regulated in cardiac disease to approximately the levels at which they were overexpressed. In both instances, we identified mRNA targets that were not predicted by TargetScan. These findings demonstrate a significant impact of other determinants of miR-mRNA interactions on RISCome recruitment, suggesting roles for nonseed sequence complementation, the number of complementary miR sequences in a given transcript, and the cumulative effects of other miRs on the same transcript.
Programming cardiomyocytes with transgenic miRs was used to hyperenrich the RISCome with strong miR targets (which are already present in the RISCome because of effects of endogenous miRs) and to identify weaker miR targets (new RISCome mRNAs). We took advantage of the Myh6 promoter to drive miR expression so that miR content, and RISCome mRNA profiles, was selectively altered in cardiac myocytes of the heart. Although nonmyocytes comprise Ϸ30% of ventricular mass, only the transcriptomes and RISComes of cardiomyocytes are affected by our genetic manipulations. Thus, the comparison between nontransgenic and transgenic RISC-Seq subtracts nonmyocyte information.
The RISCome programming approach raises the possibility of antithetic experiments to "deprogram" the RISCome, ie, RISC-Seq of miR knockout models. In the case of miR-133, the severe pathology resulting from miR-133 ablation (embryonic lethality or aggressive car- diomyopathy 27 ) precludes a meaningful analysis; secondary effects of altered miR and mRNA expression in the diseased hearts would obfuscate any primary change in RISCome mRNA content caused by absent miR-133. Furthermore, we think that RISC deprogramming is likely to be of limited utility even in the absence of a confounding phenotype because legitimate mRNA targets of the absent miR will continue to be recruited to the RISC by miR family members having similar sequences (see Figure 6 ).
In addition to providing comprehensive and unbiased analysis of RISComes in pathophysiological context, we believe RISC-Seq in tissues programmed with endogenous miRs will be useful to identify unsuspected mRNA targets having imperfect seed sequence complementarity or extraseed sequence binding, which are generally overlooked by bioinformatics. mRNA targets with perfect seed sequence complementation to a highly expressed miR are likely to already be present in the cardiac RISCome and may be less enriched by the presence of more miR than weaker targets. We observed this with Srf, an experimentally validated miR-133a target 27 that is 2.4-fold RISC-enriched in miR-133a-programmed hearts, but did not meet our criteria for statistical significance (PϽ0.0001), and with Sox6, a validated 31 miR-499 target that is already 5.1-fold RISC-enriched in nontransgenic hearts and only increases a further 1.2-fold (below our threshold for 1.3-fold change) in miR-499 programmed hearts. Thus, RISC programming with endogenously expressed miRs may have the greatest proportional impact on the less obvious, and most difficult to define, mRNA targets. Perhaps in combination with RNA footprinting to define miR-mRNA binding domains 11 and proteomics studies to elucidate the biology of miR effects, 12 RISC-Seq will be especially useful to define the in vivo targets of synthetic "designer" miRs and miR-mimetics undergoing evaluation as therapeutics.
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